Tango Therapeutics Inc’s (TNGX) Stock: A 61.03% Annual Performance Rate

The stock of Tango Therapeutics Inc (TNGX) has gone up by 2.26% for the week, with a -33.45% drop in the past month and a -23.05% drop in the past quarter. The volatility ratio for the week is 6.56%, and the volatility levels for the past 30 days are 6.11% for TNGX. The simple moving average for the last 20 days is -14.52% for TNGX stock, with a simple moving average of -6.22% for the last 200 days.

Is It Worth Investing in Tango Therapeutics Inc (NASDAQ: TNGX) Right Now?

The 36-month beta value for TNGX is at 0.85. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for TNGX is 52.47M, and currently, shorts hold a 16.93% of that float. The average trading volume for TNGX on April 04, 2024 was 691.92K shares.

TNGX) stock’s latest price update

Tango Therapeutics Inc (NASDAQ: TNGX) has seen a rise in its stock price by 1.59 in relation to its previous close of 7.56. However, the company has experienced a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-18 that Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.

Analysts’ Opinion of TNGX

Many brokerage firms have already submitted their reports for TNGX stocks, with Piper Sandler repeating the rating for TNGX by listing it as a “Overweight.” The predicted price for TNGX in the upcoming period, according to Piper Sandler is $18 based on the research report published on February 12, 2024 of the current year 2024.

B. Riley Securities, on the other hand, stated in their research note that they expect to see TNGX reach a price target of $16. The rating they have provided for TNGX stocks is “Buy” according to the report published on December 08th, 2023.

H.C. Wainwright gave a rating of “Buy” to TNGX, setting the target price at $10 in the report published on October 20th of the previous year.

TNGX Trading at -28.46% from the 50-Day Moving Average

After a stumble in the market that brought TNGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.06% of loss for the given period.

Volatility was left at 6.11%, however, over the last 30 days, the volatility rate increased by 6.56%, as shares sank -31.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.93% lower at present.

During the last 5 trading sessions, TNGX rose by +2.26%, which changed the moving average for the period of 200-days by +112.74% in comparison to the 20-day moving average, which settled at $8.81. In addition, Tango Therapeutics Inc saw -22.42% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TNGX starting from Third Rock Ventures IV, L.P., who sale 162,500 shares at the price of $12.00 back on Feb 20 ’24. After this action, Third Rock Ventures IV, L.P. now owns 19,201,475 shares of Tango Therapeutics Inc, valued at $1,950,000 using the latest closing price.

Weber Barbara, the Chief Executive Officer of Tango Therapeutics Inc, sale 4,457 shares at $12.62 during a trade that took place back on Feb 07 ’24, which means that Weber Barbara is holding 1,535,167 shares at $56,246 based on the most recent closing price.

Stock Fundamentals for TNGX

Current profitability levels for the company are sitting at:

  • -3.13 for the present operating margin
  • 0.89 for the gross margin

The net margin for Tango Therapeutics Inc stands at -2.72. The total capital return value is set at -0.32. Equity return is now at value -40.49, with -23.44 for asset returns.

Based on Tango Therapeutics Inc (TNGX), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.03. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is 196.51.

Currently, EBITDA for the company is -111.76 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 21.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.54.


In conclusion, Tango Therapeutics Inc (TNGX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts